Ticker

Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost and balance sheet actions while outlining expectations for a return to growth in 2026 during the company's fourth-quarter and full-year 2025 earnings call. Management points to refinancing, manufacturing consolidation, and governance changes President and CEO John Duke said 2025 represented a "pivotal year

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or…

Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company's 1-for-10 reverse stock split (the “Reverse Split”) of the…

Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $0.57 and traded as high as $0.60. Harvard Bioscience shares last traded at $0.5655, with a volume of 204,569 shares trading hands.